Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Waskyra Coverage & Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0862

    Waskyra (etuvetidigene autotemcel) coverage for Wiskott-Aldrich Syndrome

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0862 alerts

    Get alerted when Policy IC-0862 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing, eligibility, and administration requirements for Waskyra (etuvetidigene autotemcel) provided to members with Wiskott-Aldrich Syndrome under Viva Health.

    Policy Summary
    PayerViva Health
    PolicyWaskyra (etuvetidigene autotemcel) coverage for Wiskott-Aldrich Syndrome
    Policy CodePolicy IC-0862
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit required supporting clinical documentation (medical records, chart notes, lab results, confirmatory diagnostics) via the PA web portal or fax when requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 doseinitial authorization provided
    no renewalrenewal permitted
    J3386HCPCS code
    D82.0ICD-10

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=6 mo
    min age

    Coverage Criteria

    Initial Therapy (Medical Necessity)

    Covered when ALL of the following are met for Wiskott-Aldrich Syndrome (WAS):

    Initial Approval Criteria: Member is at least 6 months of age;
    Initial Approval Criteria: Member has a diagnosis of Wiskott-Aldrich Syndrome confirmed by a mutation in the WAS gene (gene mutation testing);

    AND member meets one of

    • Severe phenotype: Severe-phenotype WAS mutation
    • Clinical severity: Signs and symptoms consistent with classic severe WAS phenotype (Zhu-Clinical or WAS-Severity Score >= 3)
    • Absent protein: Absent WAS protein (WASP) expression
    Initial Approval Criteria: Member is a candidate for allogeneic hematopoietic stem cell transplant (HSCT) and has not had prior allogeneic HSCT;
    Initial Approval Criteria: Member does not have a suitable HLA-matched related stem cell donor;
    Initial Approval Criteria: Member does NOT have any FDA-labeled contraindications to Waskyra (examples include hypersensitivity to active substance or excipients, prior HSCT within 6 months with residual donor cells, prior hematopoietic stem cell gene therapy, or contraindications to mobilization/conditioning);
    Initial Approval Criteria: Waskyra will be used as single-agent therapy (concurrent use only permitted for lymphodepleting/conditioning or bridging therapy while awaiting manufacture);
    Initial Approval Criteria: Member will be monitored for signs and symptoms of infection before and after infusion, and prophylactic antimicrobials will be administered per local guidelines;
    Initial Approval Criteria: Immunoglobulin G (IgG) serum levels will be maintained above 5 g/L;
    Initial Approval Criteria: Member will be monitored for veno-occlusive disease (assess liver function tests) during the first month following infusion;
    Initial Approval Criteria: Member will undergo mobilization with granulocyte-colony-stimulating factor (G-CSF) and plerixafor prior to apheresis;

    See dosing/administration for collection and back-up requirements

    Initial Approval Criteria: Member will be monitored for lentiviral vector (LVV)-mediated insertional oncogenesis and secondary malignancies as clinically indicated;
    Initial Approval Criteria: Member has been screened and found negative for HIV using non-PCR methods prior to mobilization/apheresis (note: PCR assays may yield false-positive results after LVV exposure);
    Initial Approval Criteria: Live-virus vaccines will not be administered until immune reconstitution is complete;
    Initial Approval Criteria: Member will not receive antiretroviral medications (stop at least 1 month prior to mobilization and do not resume until at least 7 days after Waskyra infusion);

    Renewal Therapy

    Renewal criteria

    Renewal: Duration of authorization has not been exceeded; prior authorization is provided for one dose (one treatment) and may NOT be renewed.

    No renewals permitted per policy

    Coverage is excluded for members with any FDA-labeled contraindication to Waskyra. Examples include: hypersensitivity to etuvetidigene autotemcel or any excipients, prior allogeneic hematopoietic stem cell transplant (HSCT) within 6 months before screening or HSCT with evidence of residual donor cells, previous hematopoietic stem cell gene therapy, or other conditions that contraindicate the required mobilization and conditioning regimens. These contraindications must be assessed and documented prior to approval.

    Prior authorization is granted for a single treatment only. The policy provides initial authorization for one dose total and explicitly states that prior authorization may not be renewed. Requests for additional or repeat doses beyond that single authorized treatment are not permitted.

    Initial Therapy (Drug-specific)

    Initial Therapy (Drug-specific)

    Initial approval requires demonstration of clinical and genetic criteria plus adherence to preparatory, administration, and monitoring requirements.

    Initial Therapy Details: Member >= 6 months of age; confirmed WAS gene mutation AND one of: severe-phenotype mutation OR clinical severity score >=3 OR absent WAS protein expression;
    Initial Therapy Details: Candidate for allogeneic HSCT with no prior allogeneic HSCT and no suitable HLA-matched related donor;
    Initial Therapy Details: Confirm no FDA-labeled contraindications to Waskyra (e.g., hypersensitivity, recent HSCT within 6 months with residual donor cells, prior stem cell gene therapy, contraindications to mobilization/conditioning);
    Preparatory steps:

    Continuation / Renewal

    Continuation Therapy

    Continuation/renewal not permitted

    Continuation: Prior authorization validity may NOT be renewed; only one dose authorized per member as initial approval.

    Coding and Quantity Limits

    Covered HCPCS CodesHCPCSCovered
    J3386Injection, etuvetidigene autotemcel, per treatment; 1 billable unit = 1 treatment
    Covered ICD-10 CodesICD-10Covered
    D82.0Wiskott-Aldrich syndrome
    inv-07: Maximum product volume
    Maximum product volume< 20% of member's estimated plasma volume
    When multiple bags are usedEnsure total DMSO remains < 1% of estimated plasma volume and only one bag infused at a time
    Verify compatibility prior to infusionConfirm combined product volume is compatible with DMSO and plasma volume limits before infusion
    inv-08: DMSO limit
    Total DMSO limit< 1% of member's estimated plasma volume (total DMSO administered when multiple bags used)
    Infusion sequencingWhen multiple bags are needed, infuse only one bag of medicinal product at a time to control DMSO exposure

    Provider Actions & Documentation

    Prior Authorization

    Prior authorization — single dose

    Prior authorization is required and will be provided for one dose only. One treatment equals one billable unit (J3386); prior authorization may NOT be renewed.

    • HCPCS code for billing per treatment: J3386
    Step Therapy

    Dosing and preparatory steps — mobilization, collection, premedication, and volume/DMSO limits

    Follow required dosing, mobilization, collection, storage, and administration steps prior to conditioning and infusion: perform mobilization and apheresis to collect CD34+ cells, collect and cryopreserve a back-up supply of ≥ 3 x 10^6 CD34+ cells/kg, do not begin reduced‑intensity conditioning until complete infusion bag(s) are received and back‑up confirmed, premedicate (e.g., IV chlorpheniramine 0.2 mg/kg, max 10 mg, 15–30 minutes before infusion), and ensure product volume and DMSO limits are observed when multiple bags are used.

    • Collect required CD34+ cells by apheresis after mobilization with G‑CSF and plerixafor.

    Definitions

    inv-14: Back-up collection
    Back-up collection requirementCollect and cryopreserve a back-up supply of CD34+ stem cells containing at least 3 x 10^6 CD34+ cells/kg from the member before initiating conditioning
    Purpose of back-upStored for potential rescue in cases of product compromise, primary engraftment failure, or prolonged bone marrow aplasia
    TimingComplete back-up collection and confirm availability prior to starting reduced-intensity conditioning and infusion

    Step Therapy Requirements

    StepRequirementTiming / Notes
    {"text":"1","status":""}|{"text":"Perform mobilization with G-CSF and plerixafor to mobilize CD34+ hematopoietic stem cells for collection.","status":""}|{"text":"Before apheresis; mobilization precedes collection and conditioning (per policy dosing/administration).","status":""}
    {"text":"2","status":""}|{"text":"Perform apheresis to collect the CD34+ cells required for Waskyra manufacturing.","status":""}|{"text":"Collect cells after mobilization and prior to reduced-intensity conditioning; collected product used for manufacturing.","status":""}
    {"text":"3","status":""}|{"text":"Collect and cryopreserve a back-up supply of CD34+ stem cells containing at least 3 x 10^6 CD34+ cells/kg.","status":""}|{"text":"Must be completed before initiating reduced-intensity conditioning and infusion; backup stored for potential rescue (product compromise, primary engraftment failure, prolonged aplasia).","status":""}
    {"text":"4","status":""}|{"text":"Confirm receipt and on-site storage of the complete set of infusion bag(s) and availability of the back-up collection prior to beginning conditioning.","status":""}|{"text":"Do not begin conditioning until complete infusion bag(s) received and back-up confirmed at administration site.","status":""}
    {"text":"5","status":""}|{"text":"Ensure product volume and DMSO limits are observed when multiple bags are used: total DMSO administered < 1% of estimated plasma volume; maximum product volume < 20% of estimated plasma volume.","status":""}|{"text":"When more than one bag is needed, only one bag should be infused at a time; limits apply to total DMSO and product volume.","status":""}

    Site of Care Requirements

    Billing Rule

    Hospital outpatient — on‑site storage and back‑up collection required

    For hospital outpatient administration, ensure on‑site receipt and storage of the complete infusion bag(s) and confirmation of the back‑up collection prior to initiating conditioning or infusion; observe product volume and DMSO limits when multiple bags are required.

    • Do not begin conditioning until the complete set of infusion bag(s) has been received and stored at the administration site and back‑up collection availability is confirmed
    • When more than one bag is needed, ensure total DMSO administered remains < 1% of the member's estimated plasma volume and maximum product volume remains < 20% of estimated plasma volume

    Background

    Wiskott-Aldrich Syndrome (WAS) is an X-linked primary immunodeficiency caused by mutations in the WAS gene that result in impaired immune function. Waskyra (etuvetidigene autotemcel) is an autologous, lentiviral vector–modified CD34+ hematopoietic stem cell gene therapy intended to restore WAS protein expression and improve immune function. Treatment requires mobilization with G-CSF and plerixafor, apheresis with collection and cryopreservation of back-up CD34+ cells, reduced‑intensity conditioning prior to infusion, and close post-infusion monitoring for infection, maintenance of immunoglobulin G > 5 g/L, liver function to assess for veno‑occlusive disease, and surveillance for lentiviral vector–mediated insertional oncogenesis and secondary malignancies.

    Policy Summary
    PayerViva Health
    PolicyWaskyra (etuvetidigene autotemcel) coverage for Wiskott-Aldrich Syndrome
    Policy CodePolicy IC-0862
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit required supporting clinical documentation (medical records, chart notes, lab results, confirmatory diagnostics) via the PA web portal or fax when requesting prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy (Drug-specific)Continuation / RenewalCoding and Quantity LimitsProvider Actions & DocumentationDefinitionsStep Therapy RequirementsSite of Care RequirementsBackground
    Perform mobilization with G-CSF and plerixafor, then perform apheresis to collect CD34+ cells and collect/cryopreserve a back-up supply of at least 3 x 10^6 CD34+ cells/kg prior to initiating reduced-intensity conditioning or infusion;

    Do not begin conditioning until complete infusion bag(s) and back-up collection are confirmed available

    Conditioning and pre-treatment: Administer rituximab approximately 22 days before Waskyra to deplete B-cells; administer reduced-intensity conditioning (busulfan + fludarabine) before infusion; do not begin conditioning until complete product received and back-up confirmed;
    Premedication and infusion: Premedicate (e.g., IV chlorpheniramine 0.2 mg/kg, max 10 mg, or equivalent) 15–30 minutes prior to infusion; ensure on-site storage of complete infusion bag(s) and confirm product volume and DMSO limits when multiple bags are used (total DMSO < 1% of estimated plasma volume; total product volume < 20% of estimated plasma volume);

    Only one bag should be infused at a time when multiple bags are required

    Monitoring and safety: Monitor for infection; maintain IgG > 5 g/L; monitor LFTs for veno-occlusive disease during first month; monitor for LVV-mediated insertional oncogenesis and secondary malignancies;
    HIV and vaccination considerations: Screen negative for HIV using non-PCR methods prior to mobilization/apheresis; avoid live-virus vaccines until immune reconstitution; stop antiretrovirals at least 1 month prior to mobilization and until at least 7 days after infusion;
    Pre-infusion checkCalculate cumulative DMSO across all bags and confirm remains below 1% of plasma volume before starting infusion
    inv-18: Waskyra (etuvetidigene autotemcel)
    Billing unit1 billable unit = 1 treatment (J3386)
    Per-dose definitionOne treatment corresponds to the complete set of infusion bag(s) comprising the therapeutic dose
    Maximum cells per treatmentUp to 8.05 x 10^8 CD34+ cells/mL per treatment (as defined in dosage limits)
  1. Store back-up collection (≥ 3 x 10^6 CD34+ cells/kg) before initiating conditioning.
  2. Do not begin conditioning until complete set of infusion bag(s) is received and back‑up confirmed.
  3. Premedicate with IV chlorpheniramine (0.2 mg/kg, max 10 mg) or equivalent 15–30 minutes prior to infusion.
  4. When multiple bags are needed, ensure total DMSO < 1% of estimated plasma volume and total product volume < 20% of estimated plasma volume; infuse one bag at a time.
  5. Documentation Required

    Required supporting documentation — submit with PA request

    Submit supporting clinical documentation with the PA request via direct upload to the PA web portal or fax. Required records include medical records, chart notes, laboratory results, and confirmatory diagnostics (e.g., genetic/mutational testing) to document diagnosis, step therapy, and clinical markers.

    • Include documentation of WAS diagnosis (WAS gene mutation testing) and clinical severity or WASP expression when applicable.
    • Provide records of mobilization/apheresis and back‑up collection details.
    • Provide lab results and any other confirmatory diagnostics referenced in the request.
    Denial Risk

    Documentation submission required — risk of denial or delay if not provided

    Failure to submit the required supporting clinical documentation (medical records, chart notes, lab results, confirmatory diagnostics) at the time of request may result in denial of the authorization due to inability to establish medical necessity or may delay processing.

    • Submit records via PA web portal upload or by fax as instructed.
    • Missing documentation will be reviewed at time of submission and can lead to denial.